Core Insights - Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, published a peer-reviewed research article analyzing biomarkers in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study focuses on two biomarkers, DNMT3A and GMPS, and their prognostic significance in HCC and PDAC, highlighting that their relevance is context-dependent, influenced by immune composition and metabolic pathways [2] - The research integrates data from over 7,000 patients, providing a comprehensive analysis of survival outcomes and tumor microenvironment [2] Group 2: Educational Mission - The Brush and Key Foundation aims to mentor young scholars through hands-on research experiences, fostering critical thinking and professional development [3][5] - The collaborative environment of the foundation enhances the quality of research and builds confidence in young researchers [4] Group 3: Company Background - Oncotelic Therapeutics, established in 1988, focuses on oncology drug development, particularly for rare pediatric cancers and other malignancies [6] - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is developing treatments for various conditions, including Parkinson's Disease and erectile dysfunction [7][8]